ONESOURCE SPECL PHARMA L Share Price
ONESOURCE SPECL PHARMA L Share Price Today
As of 4 Jul 2026, ONESOURCE SPECL PHARMA L share price is ₹1,669.00. The stock opened at ₹1,707.90, compared to its previous close of ₹1,687.60. During today's trading session, ONESOURCE SPECL PHARMA L share price moved in the range of ₹1,661.50 to ₹1,740.00, with an average price of ₹1,700.75 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,057.00 and a high of ₹2,088.00. On the performance front, ONESOURCE SPECL PHARMA L share price has declined by 7.25% over the last six months and is down 16.53% on a year-on-year basis.
ONESOURCE SPECL PHARMA L Returns Calculator
ONESOURCE SPECL PHARMA L Shareholder Returns
ONESOURCE SPECL PHARMA L Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
ONESOURCE SPECL PHARMA L Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,444.85 | ₹171.92 | ₹38.71 | ₹128.18 |
| Other Income | ₹17.47 | ₹4.23 | ₹2.69 | ₹3.67 |
| Total Revenue | ₹1,462.33 | ₹176.14 | ₹41.41 | ₹131.85 |
| Total Expenses | ₹1,418.55 | ₹425.90 | ₹312.63 | ₹231.76 |
| Profit Before Tax | -₹67.07 | -₹365.70 | -₹415.65 | -₹99.91 |
| Tax | -₹49.79 | ₹0.00 | ₹0.00 | -₹0.11 |
| Profit After Tax | -₹17.28 | -₹365.70 | -₹415.65 | -₹99.80 |
| EPS - Basic | -₹1.63 | -₹94.15 | -₹200.87 | -₹65.25 |
| EPS - Diluted | -₹1.63 | -₹94.15 | -₹200.87 | -₹65.25 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹67.76 | -₹391.17 | -₹799.83 | -₹231.16 |
| Income before WC changes | ₹359.04 | -₹103.08 | -₹195.51 | -₹83.74 |
| Change in Assets | -₹287.99 | -₹77.49 | -₹36.86 | -₹370.13 |
| Change in Liabilities | -₹131.89 | ₹73.36 | ₹58.56 | ₹37.98 |
| Change in WC | -₹419.89 | -₹4.13 | ₹21.70 | -₹332.15 |
| Cash flow from Operations | -₹67.85 | -₹107.21 | -₹162.88 | -₹415.89 |
| Cash flow from Investing | -₹201.08 | ₹510.55 | -₹67.72 | -₹691.60 |
| Cash flow from Financing | ₹412.01 | -₹390.54 | ₹118.32 | ₹1,161.96 |
| Total Cash Flow | ₹143.07 | ₹12.79 | -₹112.28 | ₹54.47 |
| Cash (Start of the year) | ₹22.26 | ₹9.47 | ₹121.76 | ₹67.29 |
| Cash (End of the year) | ₹165.36 | ₹22.26 | ₹9.47 | ₹121.76 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹6,464.06 | ₹1,132.23 | ₹1,780.40 | ₹1,931.26 |
| Current Assets | ₹1,086.18 | ₹176.38 | ₹228.40 | ₹511.10 |
| Total Assets | ₹7,550.24 | ₹1,308.61 | ₹2,008.81 | ₹2,442.36 |
| Current Liabilities | ₹1,113.56 | ₹630.59 | ₹865.22 | ₹808.69 |
| Net Current Asset | -₹27.38 | -₹454.21 | -₹636.81 | -₹297.60 |
| Non-Current Liabilities | ₹556.10 | ₹282.31 | ₹358.14 | ₹621.19 |
| Equity Capital | ₹5,880.58 | ₹395.71 | ₹785.45 | ₹1,012.48 |
| Total Equity & Liabilities | ₹7,550.24 | ₹1,308.61 | ₹2,008.81 | ₹2,442.36 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,299.59 | ₹171.92 | ₹38.71 | ₹132.13 |
| Other Income | ₹17.68 | ₹4.23 | ₹2.70 | ₹5.86 |
| Total Revenue | ₹1,317.27 | ₹176.14 | ₹41.42 | ₹137.99 |
| Total Expenses | ₹1,226.48 | ₹425.14 | ₹312.56 | ₹367.73 |
| Profit Before Tax | -₹21.46 | -₹364.93 | -₹429.55 | -₹229.74 |
| Tax | -₹41.46 | ₹0.00 | ₹0.00 | ₹0.00 |
| Profit After Tax | ₹20.00 | -₹364.93 | -₹429.55 | -₹229.74 |
| EPS - Basic | ₹1.75 | -₹93.97 | -₹200.69 | -₹58.76 |
| EPS - Diluted | ₹1.75 | -₹93.97 | -₹200.69 | ₹0.00 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹22.15 | -₹390.40 | -₹799.11 | -₹229.74 |
| Income before WC changes | ₹262.52 | -₹102.33 | -₹194.18 | -₹83.00 |
| Change in Assets | -₹303.13 | -₹79.79 | -₹37.15 | -₹370.67 |
| Change in Liabilities | ₹0.23 | ₹73.13 | ₹55.70 | ₹34.00 |
| Change in WC | -₹302.90 | -₹6.66 | ₹18.55 | -₹336.67 |
| Cash flow from Operations | -₹47.28 | -₹108.99 | -₹164.70 | -₹419.66 |
| Cash flow from Investing | -₹300.04 | ₹505.99 | -₹65.68 | -₹684.54 |
| Cash flow from Financing | ₹417.22 | -₹384.22 | ₹118.32 | ₹1,158.75 |
| Total Cash Flow | ₹69.90 | ₹12.78 | -₹112.06 | ₹54.55 |
| Cash (Start of the year) | ₹22.19 | ₹9.41 | ₹121.47 | ₹66.92 |
| Cash (End of the year) | ₹92.09 | ₹22.19 | ₹9.41 | ₹121.47 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹6,366.58 | ₹1,132.16 | ₹1,780.23 | ₹1,933.33 |
| Current Assets | ₹1,023.88 | ₹176.42 | ₹228.21 | ₹511.67 |
| Total Assets | ₹7,390.46 | ₹1,308.58 | ₹2,008.44 | ₹2,445.00 |
| Current Liabilities | ₹1,069.48 | ₹628.52 | ₹863.59 | ₹808.31 |
| Net Current Asset | -₹45.60 | -₹452.10 | -₹635.38 | -₹296.64 |
| Non-Current Liabilities | ₹400.88 | ₹282.31 | ₹358.14 | ₹621.18 |
| Equity Capital | ₹5,920.10 | ₹397.74 | ₹786.71 | ₹1,015.51 |
| Total Equity & Liabilities | ₹7,390.46 | ₹1,308.58 | ₹2,008.44 | ₹2,445.00 |
About ONESOURCE SPECL PHARMA L
OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. It operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The Company specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The Company caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
ONESOURCE SPECL PHARMA L Financial Highlights
- Revenue: ONESOURCE SPECL PHARMA L reported revenue of ₹1,436.61 crore in FY26 vs ₹1,462.32 crore in FY25. It showed a decrease of 1.76% on a yearly basis.
- Operating Profit: ONESOURCE SPECL PHARMA L reported an operating loss of ₹91.96 crore in FY26 vs ₹67.07 crore in FY25. It showed a decrease of 37.11% on a year-on-year basis.
- Net Profit: ONESOURCE SPECL PHARMA L reported a net loss of ₹73.80 crore in FY26 vs ₹17.97 crore in FY25. It showed a decrease of 310.68% on a yearly basis.
ONESOURCE SPECL PHARMA L Quarterly Result Highlights
- ONESOURCE SPECL PHARMA L reported revenue of ₹430.31 crore in Mar 2026, compared with ₹294.97 crore in Dec 2025, representing an increase of 45.88% on a quarter-on-quarter (QoQ) basis.
- ONESOURCE SPECL PHARMA L reported an operating loss of ₹0.29 crore in Mar 2026, compared with ₹93.01 crore in Dec 2025, representing an increase of 99.69% on a quarter-on-quarter (QoQ) basis.
- ONESOURCE SPECL PHARMA L reported a profit of ₹4.60 crore in Mar 2026, compared with ₹88.70 crore in Dec 2025, reflecting an increase of 105.19% on a QoQ basis.
- The earnings per share (EPS) of ONESOURCE SPECL PHARMA L stood at ₹1.63 during Mar 2026.
Similar Stocks
FAQs on ONESOURCE SPECL PHARMA L Share Price
What is ONESOURCE SPECL PHARMA L share price today?
ONESOURCE SPECL PHARMA L share price is ₹1,669.00 as on 03 Jul, 2026, 15:57 IST.
How has the ONESOURCE SPECL PHARMA L share price performed in the past?
In the last 1 year, ONESOURCE SPECL PHARMA L delivered a return of -16.53%. The ONESOURCE SPECL PHARMA L share price hit a high of ₹2,088.00 and low of ₹1,057.00.
How much is the Mutual Fund shareholding in ONESOURCE SPECL PHARMA L shares?
The Mutual Fund Shareholding in ONESOURCE SPECL PHARMA L was 10.13% at the end of Mar 2026.
What is the the 52-week high and low of ONESOURCE SPECL PHARMA L shares ?
The 52-week high and low of ONESOURCE SPECL PHARMA L share is ₹2,088.00 and ₹1,057.00 as of 03 Jul, 2026.
What is the market cap of ONESOURCE SPECL PHARMA L?
The market capitalisation of ONESOURCE SPECL PHARMA L is ₹19,345.30 Crores as on 03 Jul, 2026.
What are the stock symbols of ONESOURCE SPECL PHARMA L?
The stock symbol of ONESOURCE SPECL PHARMA L is ONESOURCE on the NSE, 544292 on the BSE, and the ISIN is INE013P01021.
What was yesterday's closing price of ONESOURCE SPECL PHARMA L shares ?
ONESOURCE SPECL PHARMA L shares closed yesterday at ₹1,687.60 on NSE & ₹1,687.40 on BSE
How to buy ONESOURCE SPECL PHARMA L shares?
To buy ONESOURCE SPECL PHARMA L shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy ONESOURCE SPECL PHARMA L shares on Holidays?
No, shares of ONESOURCE SPECL PHARMA L or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell ONESOURCE SPECL PHARMA L shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of ONESOURCE SPECL PHARMA L?
The PE and PB ratio of ONESOURCE SPECL PHARMA L is -262.02 and 3.32 respectively, as on 03 Jul, 2026, 15:57 IST.
